Hochster hs et al. j clin oncol 2008 26:3523
NettetHochster HS, et al. J Clin Oncol 2008; 26:3523. Cercek A, et al. J Oncol Pract 2016; 12:e459. Oxaliplatin injection. United States Prescribing Information. US National … Nettet1. aug. 2024 · J Clin Oncol. 2024 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2024 May 1. Authors Heinz-Josef Lenz 1 , Fang-Shu Ou 2 , Alan P Venook 3 , Howard S Hochster 4 , Donna Niedzwiecki 5 , Richard M Goldberg 6 , Robert J Mayer 7 , Monica M Bertagnolli 8 ...
Hochster hs et al. j clin oncol 2008 26:3523
Did you know?
NettetHochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab … NettetJ Clin Oncol 2008;26:5910-7. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523-9. Cite this article as: Fakih M. The International Duration ...
Nettet10. okt. 2012 · This study is registered with ClinicalTrials.gov, number NCT00677443. Findings Between May 14, 2008, and Sept 23, 2009, we randomly assigned 168 patients to receive SOX and 172 to receive CapeOX. Nettet23. jun. 2015 · J Clin Oncol. 2004;22:23–30. Article PubMed CAS Google Scholar Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523–9.
Nettet12. apr. 2024 · Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, … Nettet21. sep. 2016 · DOI: 10.1200/JCO.2007.15.4138 Journal of Clinical Oncology - published online before print September 21, 2016 . PMID: 18640933
Nettet10. sep. 2008 · Journal of Clinical Oncology: Vol 26, No 26 Vol. 26, No. 26, September 10, 2008 COMMENTARY Extraosseous Ewing's Sarcoma: 25 Years Later Zagar et al. pp. …
Nettet21. sep. 2016 · Supplements Abstract Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC). Patients and Methods the wakefield savings bankNettet12. mai 2010 · In the 57 patients assessed for response, the overall response rate was 72% (95% confidence interval, 58.5–83.0). Median progression-free survival was 11.0 months (95% confidence interval, 9.6–12.5) and median overall survival was 27.4 months (95% confidence interval, 22.0–not calculated). the wakefield schemeNettetJ Clin Oncol. 2007;25(30):4779–4786. 35. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–3529. 36. the wakefield inn wakefield nhNettet1. aug. 2024 · Conclusion: These findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward … the wakefield school the plainsNettet20. apr. 2008 · Patients and methods: Patients with MCRC were randomly assigned, in a 2 x 2 factorial design, to XELOX versus FOLFOX-4, and then to bevacizumab versus … the wakefield millNettet21. sep. 2016 · Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab. Patients and Methods the wakefield arms wakefieldNettetSafety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the the wakefield item